Pinealon[Glu-Asp-Arg; EDR peptide]
Compound snapshot
Class
Research peptide
FDA approved
No
Clinical development
Phase 2
Last reviewed
September 2026
Research areas
Cognition / Mood / Neuroprotection
Regulatory status
Research use only — not approved
Internet attention
Moderate
Registry query
Pinealon
A synthetic three-amino-acid peptide from the Russian short-peptide bioregulator program, promoted for brain ageing and cognition. It has not been established as a medicine by major regulators.
Reality check — what we actually know
Supported by human evidence
- No adequately powered randomised human trials establish the outcomes this compound is marketed for.
Animal research only
- Reduced oxidative-stress markers and necrotic cell death in cultured neuronal and other cells
- Improved selected learning and stress measures in limited rodent studies
- Studied in aged-rat models of hypoxia and hypothermia
Mechanistically plausible
- Cell studies report changes in reactive-oxygen-species accumulation, ERK signalling and cell-cycle activity. Broader claims that the tripeptide directly regulates specific genes remain speculative and have not been independently validated.
Common internet claims
- Online discussion frequently presents Pinealon as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for Pinealon, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Cell studies report changes in reactive-oxygen-species accumulation, ERK signalling and cell-cycle activity. Broader claims that the tripeptide directly regulates specific genes remain speculative and have not been independently validated.
- Reduced oxidative-stress markers and necrotic cell death in cultured neuronal and other cells
- Improved selected learning and stress measures in limited rodent studies
- Studied in aged-rat models of hypoxia and hypothermia
Strength of the evidence: Very low certainty. Evidence is limited to cell and animal studies, much of it from the originating research network and Russian-language journals. No controlled human trial establishes cognitive or longevity benefit.
Safety and known cautions
No approved indication, established human safety profile or independently confirmed mechanism. It should not replace evaluation for memory change, cognitive decline, depression or neurological symptoms.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1
- Phase 2Current
- Phase 3
- Regulatory review
- Approved